# 2025 NAPT Member Survey: EXECUTIVE SUMMARY

Key data on proton therapy in the U.S.


Since 2012, the National Association for Proton Therapy (NAPT) has conducted an annual member survey designed to reveal key metrics regarding the patient and provider ecosystem evolving from one of the world's most innovative cancer treatments. The only survey of its kind in the U.S., it yields insights including changes in the mix of conditions treated by proton therapy, treatment centers by type, industry growth, the impact of prior authorizations, and other trends and challenges.


NAPT survey responses and data from public sources reveal a stable and maturing cancer treatment community. A majority of proton therapy centers are affiliated with hospitals and academic institutions. Additionally, the number and variety of conditions treated by proton therapy are increasing, and more patients who have previously undergone radiation for cancerous conditions are seeking proton therapy as a treatment option.

### **Centers and Patients**

- There are **46 operating** proton therapy centers in the United States as of December 31, 2024.
- The number of patients receiving proton therapy increased by 1,081 patients in 2023, to 18,202 nationwide in 2024.
- The number of re-irradiation patients has increased among those receiving proton therapy, from 2,800 in 2023 to 3,044 in 2024.

#### TREATMENT CENTERS BY TYPE








# PROTON CENTERS DEVELOPED:

## MULTI CENTER VS. SINGLE ROOM

Smaller single room centers have dominated recent growth in proton therapy centers in recent years.



### **Conditions Treated**

Treatment center continue to open, and the publication of new evidence regarding efficacy continues to emerge. From 2023 to 2024, the mix of conditions treated by proton therapy for these cancer types has changed as follows, by number of patients:

Breast: +1.9%

Gl Tract: +7.0%

Head & Neck: +2.5%

In 2024, most reporting centers continued to utilize **hypofractionation** for both breast and prostate cancer, though practice patterns varied significantly. These trends reflect ongoing shifts in clinical practice and highlight the need for continued evaluation of treatment approaches across disease sites.



Access to proton therapy remains constrained, with many patients facing administrative hurdles and significant travel distances to receive care.

- Proton therapy currently represents less than 2% of all radiation oncology treatments by modality.
- Approximately 65% of the U.S. population lives more than 100 miles from a treatment center.

While prior authorization continues to delay care for patients, improvements are underway, with more patients ultimately gaining approval on appeal and in a more timely manner.

- 67.7% percent of patients in 2024 experienced an average wait time of more than 6 days for PT treatment authorization, a decrease from 73.4% in 2023.
- 70.9% of patients in 2024 "sometimes" or "often" experienced delays in care delivery due to prior authorization, a decrease from 75.8% in 2023.
- 24.0% of prior authorization requests in 2024 were initially denied but subsequently approved, an increase from 19.8% in 2023.



The proton therapy community continues to grow — two centers began treating patients in 2024, offering expanded access for patients in **North Carolina**, **Illinois**, and beyond.



Full 2025 NAPT Member Survey results are available exclusively to members.

To learn more about the benefits of membership, visit: proton-therapy.org/join-napt



The National Association for Proton Therapy (NAPT) and its members support cancer research and treatment innovation and are committed to raising awareness about the value of proton therapy among policymakers, insurers, caregivers and patients to ensure that this advanced treatment modality is affordable and available in communities across the country.

LEARN MORE: PROTON-THERAPY.ORG



national-association-for-proton-therapy

